Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Additional univariate analyses revealed that age, index fracture type and osteoporosis medication were each associated with the risk of subsequent hip/femur fractures alone and subsequent vertebral fractures alone (Supplementary Table 3).Risk factors that predict the time interval between an index fracture and any subsequent fractureVariableUnivariate analyses (any subsequent fracture)aMultivariate analysis (any subsequent fracture)aHazard ratio (95% CI)p valuebHazard ratio (95% CI)p valueb,cIndex fracture type (reference group: index vertebral fracture [n = 9133])a Index fracture: Hip/femur (n = 2705)0.69 (0.61, 0.77)< 0.0010.65 (0.58, 0.74)< 0.001 Index fracture: Forearm/wrist/hand (n = 4455)0.74 (0.67, 0.81)< 0.0010.76 (0.70, 0.84)< 0.001 Index fracture: Shoulder/upper arm (n = 2061)0.83 (0.74, 0.94)0.0030.84 (0.75, 0.95)0.006Sex (reference group: males [n = 1794]) Females [n = 16,560]1.13 (0.99, 1.29)0.0651.12 (0.98, 1.28)0.087Age group (reference group: 70 to 79 years [n = 6449]) 50 to 59 years (n = 1063)0.71 (0.59, 0.85)< 0.0010.74 (0.61, 0.88)0.001 60 to 69 years (n = 2408)0.80 (0.71, 0.91)< 0.0010.83 (0.73, 0.94)0.003 80 to 89 years (n = 6748)1.05 (0.96, 1.14)0.2711.05 (0.96, 1.14)0.280 ≥ 90 years (n = 1686)1.14 (1.00, 1.30)0.0481.17 (1.02, 1.34)0.026Osteoporosis medication (reference group: no osteoporosis medication [n = 12,029]) Bisphosphonates only (n = 5828)1.10 (1.02, 1.19)0.0201.05 (0.97, 1.14)0.206 Other osteoporosis medication (n = 885)1.10 (0.93, 1.30)0.2591.05 (0.89, 1.24)0.560Other medications (reference group: no other medications) Antidepressantsd (n = 5975)1.13 (1.05, 1.22)0.0021.07 (0.99, 1.16)0.079 Aromatase inhibitors (n = 410)0.95 (0.74, 1.23)0.706: : Diureticsd (n = 8017)1.09 (1.02, 1.18)0.0170.94 (0.86, 1.02)0.134 Glucocorticoids (4619)1.01 (0.93, 1.10)0.728: : Hormonablative therapy/antiandrogen therapy in males (n = 36)0.33 (0.08, 1.32)0.117: : Fall-inducing medications(n = 3794)1.16 (1.06, 1.26)0.0011.07 (0.98, 1.18)0.120 Proton pump inhibitor (PPI) (n = 10,632)1.12 (1.04, 1.21)0.0021.04 (0.97, 1.13)0.276 Thiazolidindiones (glitazones) in females (n = 79)1.22 (0.73, 2.02)0.452: : Charlson Comorbidity Index score (reference group: Charlson Comorbidity Index score ≤ 1 [n = 6347]) Charlson Comorbidity Index score > 1 (n = 12.007)1.18 (1.10, 1.28)< 0.0011.06 (0.97, 1.16)0.181Medical conditions (reference group: no condition) Stroke (n = 1515)1.03 (0.91, 1.18)0.630: : Myocardial infarction (n = 2371)1.09 (0.98, 1.21)0.100: : Ankylosing spondylitis (n = 145)1.25 (0.87, 1.80)0.231: : Chronic obstructive pulmonary disease (n = 7337)1.01 (0.92, 1.11)0.836: : Subclinical hypercortisolism and Cushing’s syndrome (n = 48)0.96 (0.46, 2.03)0.925: : Diabetes mellitus type 1 (n = 977)1.06 (0.90, 1.24)0.496: : Diabetes mellitus type 2 (n = 4744)1.00 (0.92, 1.08)0.920: : Epilepsy/use of antiepileptics (n = 2569)1.19 (1.08, 1.32)0.0011.13 (1.02, 1.26)0.017 Growth hormone deficiency (n = 32)0.76 (0.28, 2.02)0.576: : Heart failure (n = 5379)1.23 (1.13, 1.32)< 0.0011.12 (1.02, 1.23)0.021 Other specialized nutritional anemias (n = 6)2.42 (0.60, 9.67)0.212: : Hypoosmolality and hyponatremia (n = 897)1.17 (0.99, 1.37)0.0601.06 (0.89, 1.24)0.522 Monoclonal gammopathy of unclear significance (n = 132)0.94 (0.60, 1.48)0.793: : Primary hyperparathyroidism (n = 43)1.13 (0.56, 2.26)0.730: : Rheumatoid arthritis (n = 1941)1.13 (1.01, 1.26)0.0361.10 (0.98, 1.23)0.112 Subclinical and manifest hyperthyreosis (n = 1881)1.04 (0.93, 1.17)0.497: : Vitamin D and calcium deficiency (n = 717)0.88 (0.72, 1.07)0.207: : CI confidence intervalaAny fracture encompasses ICD-10-GM [International Classification of Diseases, 10th revision, German Modification] codes T08, S12, S22, S32, S42, S52, S62 and S72.
Source: Risk factors for subsequent fracture. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In this retrospective, observational cohort study using German real-world claims data, male and female patients aged ≥ 50 years with osteoporosis who experienced an initial (“index”) hip/femur, vertebral, forearm/wrist/hand or shoulder/upper arm fracture between 2010 and 2014 were included.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Osteoporotic fractures and subsequent fractures: imminent fracture risk from an analysis of German real-world claims data
Study design awaiting verification · Archives of Gynecology and Obstetrics · 2021
Original publication title
Osteoporotic fractures and subsequent fractures: imminent fracture risk from an analysis of German real-world claims data
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
In osteoporosis, prior fracture is a strong predictor of subsequent fracture. This study aimed to assess the imminent risk of subsequent fracture following an initial fracture in osteoporosis patients in Germany, and to identify clinical and demographic characteristics that are independently associated with subsequent fracture risk.
Source: PurposeAbstract: What methods does the paper describe?
In this retrospective, observational cohort study using German real-world claims data, male and female patients aged ≥ 50 years with osteoporosis who experienced an initial (“index”) hip/femur, vertebral, forearm/wrist/hand or shoulder/upper arm fracture between 2010 and 2014 were included. The incidence and timing of subsequent fractures during a 1-year follow-up period were analyzed. Independent risk factors for subsequent fracture were identified by multivariate regression analysis.
Source: MethodsAbstract: Results
A total of 18,354 patients (mean age: 77 years; standard deviation: 9.8) were included. Of these, 2918 (15.9%) suffered a subsequent fracture during the 1-year follow-up period. The incidence of subsequent fracture was higher following an index vertebral fracture (18.0%) than after an index forearm/wrist/hand fracture (14.1%) or index hip/femur fracture (12.1%). Subsequent 1-year fracture incidence was generally higher in older patients. Index fracture type, age, epilepsy/use of antiepileptics, and heart failure were all independently associated with subsequent fracture risk.
Source: ResultsAbstract: Conclusion
Osteoporosis patients in Germany are at imminent risk of subsequent fracture during the first year following an initial fracture. They should be targeted for immediate post-fracture treatment to reduce the risk of further fractures, especially in the presence of specific risk factors such as old age or index vertebral fracture.
Source: ConclusionAuthors’ abstract
Purpose
In osteoporosis, prior fracture is a strong predictor of subsequent fracture. This study aimed to assess the imminent risk of subsequent fracture following an initial fracture in osteoporosis patients in Germany, and to identify clinical and demographic characteristics that are independently associated with subsequent fracture risk.
Methods
In this retrospective, observational cohort study using German real-world claims data, male and female patients aged ≥ 50 years with osteoporosis who experienced an initial (“index”) hip/femur, vertebral, forearm/wrist/hand or shoulder/upper arm fracture between 2010 and 2014 were included. The incidence and timing of subsequent fractures during a 1-year follow-up period were analyzed. Independent risk factors for subsequent fracture were identified by multivariate regression analysis.
Results
A total of 18,354 patients (mean age: 77 years; standard deviation: 9.8) were included. Of these, 2918 (15.9%) suffered a subsequent fracture during the 1-year follow-up period. The incidence of subsequent fracture was higher following an index vertebral fracture (18.0%) than after an index forearm/wrist/hand fracture (14.1%) or index hip/femur fracture (12.1%). Subsequent 1-year fracture incidence was generally higher in older patients. Index fracture type, age, epilepsy/use of antiepileptics, and heart failure were all independently associated with subsequent fracture risk.
Conclusion
Osteoporosis patients in Germany are at imminent risk of subsequent fracture during the first year following an initial fracture. They should be targeted for immediate post-fracture treatment to reduce the risk of further fractures, especially in the presence of specific risk factors such as old age or index vertebral fracture.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00404-021-06123-6.
Publication and source details
Original title: Osteoporotic fractures and subsequent fractures: imminent fracture risk from an analysis of German real-world claims data
Peyman Hadji; Bernd Schweikert; Edda Kloppmann; Patrick Gille; Lars Joeres; Emese Toth; Luis Möckel; Claus-C. Glüer
Archives of Gynecology and Obstetrics · 2021
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.UCB PharmaAmgen Inc.Christian-Albrechts-Universität zu Kiel (3094)Open Access funding enabled and organized by Projekt DEAL.
Universitätsklinikum Schleswig-Holstein: Campus Kiel (6509)Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T12:08:34.583820+00:00
DOI: 10.1007/s00404-021-06123-6 · PMC8325652